45 patents currently held
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next US patent term in the Flagship Pioneering Innovations VI, LLC portfolio ends in Dec 2038, and more of its terms end in 2042 (18) than in any other year. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Dec 2038
Next term end
26
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 22, 2026 · includes USPTO assignment data published Nov 21, 2026, status data published Nov 22, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Aug 2039 · High confidence
Also notable
Ends Dec 2038 · High confidence
Also notable
Ends Aug 2042 · High confidence
Also notable
Ends Aug 2042 · High confidence
Also notable
Ends no later than Mar 2041 · Medium confidence
Agricultural Compositions and Related Methods
US 11,827,897
Cited by 11 later US patents, top 10% of utility patents granted in 2023 in our data. Protection runs to 2039.
Compositions Comprising Circular Polyribonucleotides and Uses Thereof
US 10,953,033
Cited by 8 later US patents, top 25% of utility patents granted in 2021 in our data. Protection runs to 2038.
Multiple-Tiered Screening and Second Analysis
US 11,788,152
A family of 9 related applications built on the 2023 grant. Protection runs to 2042.
Combination Therapies for the Treatment of Viral Infections
US 11,654,121
Granted 2023. Computed term ends 2042.
Methods and Compositions for Modulating a Genome
US 12,454,706
A family of 7 related applications built on the 2025 grant. Too new for citation comparison; protection runs to 2041. A terminal disclaimer is on file and its reference is not resolved, so no cap is applied and the date may move earlier, never later.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Nov 23, 2026The maintenance fee for Combination Therapies for the Treatment of Viral Infections (US 11,654,121) comes due Nov 23, 2026. Unpaid by May 24, 2027, it lapses early.
- 1 fee due Apr 17, 2027The maintenance fee for Multiple-Tiered Screening and Second Analysis (US 11,788,152) comes due Apr 17, 2027. Unpaid by Oct 18, 2027, it lapses early.
- 1 fee due May 28, 2027The maintenance fee for Agricultural Compositions and Related Methods (US 11,827,897) comes due May 28, 2027. Unpaid by Nov 29, 2027, it lapses early.
- 1 fee due Jun 19, 2027The maintenance fee for Compositions Comprising Circular Polyribonucleotides and Uses Thereof (US 11,844,759) comes due Jun 19, 2027. Unpaid by Dec 20, 2027, it lapses early.
- 3 fees due Nov 7 to 21, 2027 · next Nov 7
Recent changes
- 2 of the patents on this record were granted since Aug 24, 2026
What they patent
The largest of its 26 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
Patents held now
Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,953,033 | Compositions Comprising Circular Polyribonucleotides and Uses Thereof In force · High confidence | In force | High confidence | |
| US 11,058,706 | Compositions Comprising Circular Polyribonucleotides and Uses Thereof In force · High confidence | In force | High confidence | |
| US 11,160,822 | Compositions Comprising Circular Polyribonucleotides and Uses Thereof In force · High confidence | In force | High confidence | |
| US 11,458,156 | Compositions Comprising Circular Polyribonucleotides and Uses Thereof In force · High confidence | In force | High confidence | |
| US 11,844,759 | Compositions Comprising Circular Polyribonucleotides and Uses Thereof In force · High confidence | In force | High confidence | |
| US 12,797,405 | Compositions Comprising Circular Polyribonucleotides and Uses Thereof In force · High confidence | In force | High confidence | |
| US 12,797,406 | Compositions Comprising Circular Polyribonucleotides and Uses Thereof In force · High confidence | In force | High confidence | |
| US 12,191,023 | Systems and Methods for Patient Targeted Therapy Development In force · High confidence | In force | High confidence | |
| US 12,282,499 | Database Processing System for Determining Whether an Entity Affects a Transition In force · High confidence | In force | High confidence | |
| US 11,827,897 | Agricultural Compositions and Related Methods In force · High confidence | In force | High confidence |
Also on record, not counted in the 45: 149 applications pending · 29 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.